Purple Total Current Liabilities from 2010 to 2024
| PPBT Stock | USD 6.89 0.09 1.29% |
Total Current Liabilities | First Reported 2014-12-31 | Previous Quarter 8.5 M | Current Value 6.5 M | Quarterly Volatility 6.6 M |
Check Purple Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Purple Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 208.9 K, Interest Expense of 2.3 M or Selling General Administrative of 4.6 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 10.67 or Days Sales Outstanding of 366. Purple financial statements analysis is a perfect complement when working with Purple Biotech Valuation or Volatility modules.
Purple | Total Current Liabilities |
Latest Purple Biotech's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Purple Biotech over the last few years. Total Current Liabilities is an item on Purple Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Purple Biotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Purple Biotech's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Purple Biotech's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Purple Total Current Liabilities Regression Statistics
| Arithmetic Mean | 2,981,527 | |
| Geometric Mean | 2,380,152 | |
| Coefficient Of Variation | 69.45 | |
| Mean Deviation | 1,651,425 | |
| Median | 3,098,000 | |
| Standard Deviation | 2,070,675 | |
| Sample Variance | 4.3T | |
| Range | 6.2M | |
| R-Value | 0.82 | |
| Mean Square Error | 1.5T | |
| R-Squared | 0.68 | |
| Significance | 0.0002 | |
| Slope | 381,655 | |
| Total Sum of Squares | 60T |
Purple Total Current Liabilities History
About Purple Biotech Financial Statements
Purple Biotech shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Purple Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Purple Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Purple Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 7.2 M | 3.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.